Showing 1911-1920 of 5957 results for "".
- NIH-Led Science Team Defines Elements of Cerebral Vision Impairmenthttps://modernod.com/news/nih-led-science-team-defines-elements-of-brain-based-leading-cause-of-childhood-vision-loss/2482557/Cerebral (or cortical) vision impairment (CVI) is a leading cause of childhood vision impairment in the United States and other industrialized nations, affecting at least 3% of primary school children. As vision is closely tied to learn
- Lenz Therapeutics Completes Merger with Graphite Bio; Debuts on Nasdaqhttps://modernod.com/news/lenz-therapeutics-completes-merger-with-graphite-bio-to-debut-on-nasdaq/2482177/Lenz Therapeutics announced the completion of its previously announced merger with Graphite Bio. The new combined company will operate under the name Lenz Therapeutics and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. &ldquo
- Survey: Employees Value Vision Care as Much as Dental, but Many are Leaving Benefits on the Tablehttps://modernod.com/news/survey-employees-value-vision-care-as-much-as-dental-but-many-are-leaving-benefits-on-the-table/2481495/A new survey conducted by The Harris Poll for XP Health finds that employees value vision care as much as dental, but many are confused about how to take advantage of it—even when they have vision benefits. According to the
- Alcon Launches "Alcon Experience Academy" App, Expanding On-Demand Learninghttps://modernod.com/news/alcon-launches-experience-academy-app-expanding-remote-on-demand-learning/2481422/Alcon announced the launch of the Alcon Experience Academy (AEA) app, which aims to help optimize eye care professionals’ (ECPs) digital learning experiences. The launch of the app brings AEA’s education and training resources to customers’ fingertips. The customizable
- SightGlass Vision Presents 24-Month Data Demonstrating Myopia Control Efficacy for Vision Spectacle Lenseshttps://modernod.com/news/sightglass-vision-presents-24-month-data-demonstrating-myopia-control-efficacy-for-vision-spectacle-lenses/2480823/Spectacles that use SightGlass Vision Diffusion Optics Technology have demonstrated efficacy in slowing the progression of myopia in children,[1] based on 24-month interim data from its pivotal c
- Treehouse Eyes Partners with J&J Vision to Deliver Treatment Innovation for Myopia Management: Acuvue Abiliti Overnight Therapeutic Lenseshttps://modernod.com/news/treehouse-eyes-partners-with-jj-vision-to-deliver-treatment-innovation-for-myopia-management-acuvue-abiliti-overnight-therapeutic-lenses/2480497/Treehouse Eyes, a health care business dedicated exclusively to treating myopic chi
- Alcon Canada Introduces the Clareon IOL with the AutonoMe Preloaded Intraocular Lens Delivery Systemhttps://modernod.com/news/alcon-canada-introduces-the-clareon-iol-with-the-autonome-preloaded-intraocular-lens-delivery-system/2478820/Alcon has announced a nationwide launch of the Clareon IOL with the AutonoMe delivery system in Canada. AutonoMe is an automated, disposable, preloaded IOL delivery system that enables precise delivery of the IOL into the capsular bag in patients undergoing cataract surgery, according to
- Mojo Vision Developing Smart Contact Lenshttps://modernod.com/news/mojo-vision-developing-smart-contact-lens/2477237/Mojo Vision announced it is building what it calls the “world’s first true smart contact lens,” called the Mojo Lens. Mojo Lens is a contact lens with a built-in display that gives people useful and timely information without forcing them to look down at a screen or losing focus on th
- Bausch + Lomb Enters Licensing Agreement With Intraocular Lens Design Group Tatvum Researchhttps://modernod.com/news/bausch-lomb-enters-licensing-agreement-with-intraocular-lens-design-group-tatvum-research/2476928/Bausch + Lomb announced that it has entered into a licensing agreement with Tatvum Research, a company focused on IOL development and design. Financial terms of the deal were not disclosed. The agreement provides Bausch + Lomb with worldwide commercial rights to new IOL designs for
- Sight Sciences Raises $56M to Lead the Development of MIGS Market and Procedure-Based Dry Eye Markethttps://modernod.com/news/sight-sciences-raises-56m-to-lead-the-development-of-migs-market-and-procedure-based-dry-eye-market/2476848/Sight Sciences announced the closing of $31 million in Series D Preferred Stock financing. MidCap Financial and Sight Sciences entered into a $25 million debt facility earlier in 2019. The $56 million